Table 1.
Preoperative Characteristics of the Study Population
| Preoperative Biomarker Status | |||||
|---|---|---|---|---|---|
| hs-cTnT < 14 ng/L NT-proBNP < 300 ng/L |
hs-cTnT > 14 ng/L NT-proBNP < 300 ng/L |
hs-cTnT < 14 ng/L NT-proBNP > 300 ng/L |
hs-cTnT > 14 ng/L NT-proBNP > 300 ng/L |
Total | |
| n= 279 (48.8%) | n= 102 (17.8%) | n=53 (9.3%) |
n=138 (24.1%) | n=572 (100%) |
|
| Mean age – yr (SD) | 60.1 (9.4) | 65.8 (8.5) | 66.2 (8.6) | 70.5 (10.1) | 64.9 (10.7) |
| Male Sex, n (%) | 153 (54.8) | 76 (74.5) | 32 (60.4) | 94 (68.1) | 355 (62.1) |
| Race, n (%) | |||||
| White | 221 (79.2) | 83 (82.2) | 45 (84.9) | 112 (81.8) | 461 (80.1) |
| Black | 56 (20.1) | 18 (17.8) | 8 (15.1) | 25 (18.2) | 107 (18.8) |
| Other | 2 (0.7) | 0 | 0 | 0 | 2 (0.4) |
| Smoking history, n (%) | 218 (78.1) | 71 (69.6) | 47 (88.7) | 94 (69.1) | 430 (75.4) |
| Current smoker, n (%) | 90 (32.3) | 22 (21.5) | 22 (41.5) | 32 (23.2) | 166 (29.0) |
| Pack-years (median, IQR) | 37.5 (20; 50) | 32 (19; 60) | 40 (25; 55.5) | 40 (20; 60) | 40 (20;60) |
| Diabetes, n (%) | 83 (29.9) | 40 (39.6) | 13 (24.5) | 71 (51.8) | 207 (36.8) |
| Insulin dependent, n (%) | 24 (29.3) | 16 (40.0) | 4 (30.8) | 38 (53.5) | 82 (14.3) |
| Hypertension, n (%) | 208 (74.8) | 90 (88.2) | 48 (90.6) | 116 (84.1) | 462 (80.1) |
| Hypercholesterolemia, n (%) | 176 (63.1) | 66 (64.7) | 34 (64.2) | 97 (71.3) | 373 (65.4) |
| Chronic renal failure, n (%) | 17 (6.2) | 8 (7.9) | 3 (5.7) | 31 (22.6) | 59 (10.4) |
| On hemodialysis, n (%) | 1 (0.4) | 1 (0.4) | 0 | 4 (2.9) | 6 (1.0) |
| eGFR (median, IQR) | 90 (75;101) | 79 (62; 94) | 75 (57; 90) | 60 (46; 82) | 80 (61; 95) |
| COPD, n (%) | 35 (12.5) | 11 (10.8) | 12 (22.6) | 19 (13.8) | 77 (13.5) |
| Coronary artery disease, n (%) | 126 (45.3) | 60 (58.8) | 31 (58.5) | 105 (76.1) | 322 (56.4) |
| Previous MI, n (%) | 57 (20.4) | 27 (26.5) | 20 (37.7) | 50 (36.8) | 154 (27.0) |
| Previous PCI/stent, n (%) | 82 (29.7) | 34 (33.7) | 15 (28.3) | 62 (45.9) | 193 (34.2) |
| Previous CABG, n (%) | 28 (10.1) | 18 (17.6) | 9 (17.0) | 44 (31.9) | 99 (17.4) |
| Congestive heart failure, n (%) | 21 (7.5) | 8 (7.8) | 8 (15.1) | 32 (23.4) | 69 (12.1) |
| Peripheral vascular disease, n (%) |
84 (30.2) | 26 (26.0) | 16 (30.2) | 63 (46.0) | 189 (33.3) |
| Carotid disease, n (%) | 17 (6.2) | 13 (12.9) | 4 (7.5) | 14 (10.2) | 48 (8.5) |
| Stroke/TIA, n (%) | 34 (12.2) | 11 (10.8) | 12 (22.6) | 23 (16.8) | 80 (14.0) |
| Atrial fibrillation, n (%) | 18 (6.5) | 6 (5.9) | 8 (15.4) | 36 (26.3) | 68 (11.9) |
| Lee’s revised cardiac risk index | |||||
| I | 104 (37.5) | 32 (31.4) | 15 (28.8) | 24 (17.4) | 175 (30.8) |
| II | 121 (43.7) | 50 (49.0) | 23 (44.2) | 56 (40.6) | 250 (43.9) |
| III | 48 (17.3) | 17 (16.7) | 12 (23.1) | 39 (28.3) | 116 (20.4) |
| IV | 4 (1.4) | 3 (2.9) | 2 (3.8) | 19 (13.8) | 28 (4.9) |
| ASA status, n (%) | |||||
| II | 61 (21.9) | 18 (17.8) | 5 (9.4) | 8 (5.8) | 92 (16.1) |
| III | 211 (75.9) | 79 (78.2) | 47 (88.7) | 119 (86.2) | 456 (80.0) |
| IV | 6 (2.2) | 4 (4.0) | 1 (1.9) | 11 (8.0) | 22 (3.9) |
| hs-cTnT ng/L (median, IQR) | 8.6 (6.3; 10.5) | 18.2 (15.7; 22.4) | 10.0 (7.7; 11.8) | 23.7 (18.6; 34.8) | 12.0 (8.3; 19.3) |
| NT-proBNP ng/L (median, IQR) | 66 (35; 112) | 122 (70; 179) | 479 (360; 718) | 936 (493; 1926) | 140 (60; 421) |